Organogenesis Holdings Inc (ORGO)

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...

Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself

Issued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of...

Form 8-K - Current report

The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of...

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

CANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...

Form 4 - Statement of changes in beneficial ownership of securities